A green TLC–densitometric bioanalytical method for concurrent determination of duloxetine and risperidone in human plasma with in-silico DDI evaluation

TL;DR

This paper introduces an eco-friendly method to measure two psychiatric drugs in human plasma and evaluates their drug-drug interactions.

Contribution

A green TLC-densitometric method for measuring duloxetine and risperidone in plasma with in-silico drug-drug interaction evaluation.

Findings

A solvent system of methanol, ethylacetate, and ammonia successfully separated duloxetine and risperidone in plasma.

The method showed good linearity and environmental safety based on greenness and blueness metrics.

In-silico DDI evaluation confirmed the safety and therapeutic effectiveness of the drug combination.

Abstract

Schizophrenia is a chronic, complex and severs psychiatric disorder that impacts men and women globally. The combined use of atypical antipsychotics; risperidone (RSP), and antidepressants medications; duloxetine hydrochloride (DLX), has grown more clinical significance in cutting edge treatments of complex psychiatric conditions like schizophrenia. This research targets to develop an environmentally harmonious, selective, and accurate TLC method to measure the levels of both DLX and RSP in spiked human plasma samples. A mixture of methanol, ethylacetate, and 33% ammonia solution (6: 4: 0.2, by volume) was successfully utilized as a solvent system to separate the proposed components. A UV-scanning wavelength of 230 nm was used for detection. An internal standard; propranolol (PRP); was used to account for small variations in the samples. The resulting retardation factors (Rf) were 0.02, 0.32, 0.46 and 0.59 for plasma, DLX, PRP and RSP, respectively. The linearity ranges were 0.04–0.4 and 0.1–0.6 µg band− 1 for DLX and RSP, respectively. The suggested method’s environmental safety was evaluated using five tools and the results showed good greenness and blueness method’s characteristics. Additionally, the method’s figures of merits were within the accepted criteria, according to the US-FDA bio-analytical guidelines. Furthermore, drug-drug interactions (DDI) evaluation was conducted using web-based DDI tool to examine the interaction manifestations and to verify safety and therapeutic effectiveness of this combination.

Figures